Freedom Capital Markets maintains Inspire Medical Systems at Buy, lowers price target to $93 from $97

Freedom Capital Markets kept Inspire Medical Systems' rating at Buy but reduced its price target to $93 from $97, a 4.1% decrease. This implies a 53.6% upside from the Nov 12 close of $60.54. Recent analyst price targets for the company range from $60 to $76.

Original reporting
Published Nov 13, 2026, 7:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 7:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Freedom Capital Markets maintains Inspire Medical Systems at Buy, lowers price target to $93 from $97 — source image
Decision brief

The 30-second read

$INSPBearishLow
01

Why it matters

A lower target may prompt short‑term selling pressure, but the effect is likely modest given the small magnitude.

02

Market read

Analyst target adjustment provides a minor trading signal for INSP.

03

What to watch

Potential pipeline developments or contract wins not mentioned could offset the downgrade.

Relevance 5/10Novelty 4/10Timing: today

Background

The article reports a recent analyst action on Inspire Medical Systems, noting a price target reduction.

Company-level read

Ticker impact

$INSPBearishMedium confidence
Context

Freedom Capital Markets lowered its price target on Inspire Medical Systems to $93 from $97, indicating a fresh analyst downgrade.

Expected impact

likely modest price decline as investors price in the lower target

Evidence & confidence

Target reduction signals reduced upside expectations; no other catalyst present.

Market effects

Minimal impact on the broader medical device sector.

No significant regional effect.

Limited relevance beyond the company.

Counterpoint

The target cut may be overly cautious if upcoming product launches exceed expectations.

Key entities

  • Freedom Capital Markets

    Equity research firm issuing the target cut.

  • Inspire Medical Systems

    Medical device maker whose stock is affected.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.